Ropinirole
From Pharmacopedia
More actions
Ropinirole
Requip (IR), Requip XL (extended-release)
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Common uses
Parkinson disease, early monotherapy and advanced adjunct (FDA)0, Restless legs syndrome (FDA)0
Pharmacy
Starting dose
Parkinson disease: 0.25 mg PO TID, titrate weekly. Restless legs syndrome: 0.25 mg PO 1-3 hours before bedtime, titrate to 4 mg/day if needed
Preparations
IR tablets 0.25, 0.5, 1, 2, 3, 4, 5 mg; XL tablets 2, 4, 6, 8, 12 mg
US FDA Max
24 mg/day (Parkinson disease); 4 mg/day (restless legs syndrome)
Pharmacology
Routes
Oral
Onset
Motor improvement over days at therapeutic dose
Duration
TID dosing (IR); once-daily (XL)
Half-life
~6 hours[1]
Bioavailability
~55% (oral)[1]
Pregnancy
Limited human data.[citation needed]
Legal status
Rx-only in US
Purported mechanism
Selective non-ergot D2 and D3 dopamine receptor agonist (similar pharmacology to pramipexole, with slight D3 preference). Used in Parkinson disease as monotherapy in early disease and as adjunct to levodopa in advanced disease; first-line in moderate-to-severe restless legs syndrome.0 Same class adverse-effect profile as pramipexole: impulse control disorders (pathological gambling, hypersexuality, compulsive shopping, binge eating), somnolence with sleep attacks (potentially while driving), hallucinations, and peripheral edema. CYP1A2 substrate: ciprofloxacin raises exposure approximately 5-fold; smoking (CYP1A2 inducer) lowers exposure, requiring dose adjustment when patients start or stop smoking[1].
References
- ↑ 1.0 1.1 1.2 FDA Prescribing Information, Requip (ropinirole hydrochloride), GSK, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020658s022,021829s011lbl.pdf